Professor Psychiatry, Northern Ontario School of Medicine, Laurentian and Lakehead University, Ontario, Canada; Emeritus Professor Psychiatry, Schulich School of Medicine, Western University, Ontario, Canada.
Asian J Psychiatr. 2017 Oct;29:106-109. doi: 10.1016/j.ajp.2017.05.004. Epub 2017 May 4.
Neuroleptic Malignant Syndrome (NMS) is a life threatening complication of antipsychotic therapy. It is often assumed to be rare. Observations suggest that rather than overestimating its frequency, we are more likely to underestimate it (Pope et al., 1986). It is a rare but potentially fatal disorder characterized by four principal symptoms. These are mental status changes, muscle rigidity, hyperthermia, and autonomic dysfunction. The diagnosis of NMS often presents a challenge because several medical conditions generate similar symptoms. Although less common now than in the past, thanks to greater awareness, it remains a risk in susceptible patients receiving conventional or atypical neuroleptics. Reducing the risk factors, early recognition of suspected cases, and prompt management can significantly reduce morbidity and mortality of this dangerous condition. Collaboration between psychiatry and other medical specialities may be the key to a successful outcome.
神经阻滞剂恶性综合征(NMS)是抗精神病药物治疗的一种危及生命的并发症。它通常被认为是罕见的。观察表明,我们更有可能低估而不是高估其频率(Pope 等人,1986 年)。它是一种罕见但潜在致命的疾病,其特征是四个主要症状。这些是精神状态改变、肌肉僵硬、高热和自主功能障碍。NMS 的诊断常常具有挑战性,因为许多医疗状况会产生类似的症状。尽管由于认识的提高,现在比过去少见,但在接受传统或非典型神经阻滞剂的易感患者中,它仍然是一种风险。降低风险因素、早期识别疑似病例并及时治疗可以显著降低这种危险情况的发病率和死亡率。精神病学和其他医学专业之间的合作可能是成功治疗的关键。